Latest News - Aerie Pharmaceuticals

Friday, October 13, 2017 | Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces FDA Advisory Committee Vote in Favor of Rhopressa

In their review of Aerie Pharmaceuticals' product candidate Rhopressa (netarsudil ophthalmic solution) 0.02%, the members of Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA provide…

Read the full story

Wednesday, October 11, 2017 | Glaucoma, Aerie Pharmaceuticals

Aerie Climbs After FDA Briefing Concurs With Efficacy Claims

Aerie Pharmaceuticals has received good news going into its FDA advisory committee meeting. The FDA agreed with the efficacy conclusion Aerie reached to support its bid for approval of glaucoma and oc…

Read the full story

Thursday, October 05, 2017 | Acquisitions/Mergers, Retina, Aerie Pharmaceuticals, AMD

Aerie Pharmaceuticals Announces Drug Delivery Asset Acquisition to Advance Its Retinal Disease Program

Aerie Pharmaceuticals announced that it has acquired rights to use Envisia Therapeutics' PRINT technology in ophthalmology and certain other assets. The PRINT technology is a proprietary system ca…

Read the full story

Thursday, September 21, 2017 | Management/Leadership, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces Appointment of Tori Arens as Vice President of Drug Product Manufacturing and Eric Carlson, PhD, as Vice President of Research and Development

Aerie Pharmaceuticals announced the appointment of Tori Arens as Vice President of Drug Product Manufacturing, reporting to Kenneth Ruettimann, PhD, Aerie’s Vice President of Manufacturing. Aeri…

Read the full story

Wednesday, September 20, 2017 | Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces FDA Advisory Committee Meeting for Rhopressa

Aerie Pharmaceuticals announced that a meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA has been scheduled for October 13, 2017 to review the company’s new drug app…

Read the full story

Wednesday, September 06, 2017 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Initiates Mercury 3 Clinical Trial of Roclatan in Europe

Aerie Pharmaceuticals announced the commencement of patient dosing in Mercury 3, the company’s European phase 3 clinical trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.00…

Read the full story

Tuesday, August 08, 2017 | Earnings & Financials, Aerie Pharmaceuticals

Aerpio Pharmaceuticals Commences Trading on the OTCQB Market

Aerpio Pharmaceuticals announced that shares of the company’s common stock have been cleared for trading on the OTC Market Group's OTCQB market in the United States. Shares of Aerpio’s…

Read the full story

Wednesday, July 19, 2017 | Clinical Trials, Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Reports Positive Roclatan Phase 3, 12-Month Topline Safety Results

Aerie Pharmaceuticals reported the successful 12-month safety results of the company’s “Mercury 1” phase 3 registration trial for its fixed-dose combination product candidate, Roclat…

Read the full story

Friday, May 26, 2017 | Earnings & Financials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces Public Offering of Common Stock

Aerie Pharmaceuticals announced that it has commenced a registered underwritten public offering of $50 million of shares of its common stock. Cantor Fitzgerald & Co. is acting as the sole bookr…

Read the full story

Wednesday, May 24, 2017 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for Roclatan

Aerie Pharmaceuticals reported the successful primary efficacy results of the company’s 90-day, phase 3 Mercury 2 registration trial for its fixed-dose combination product candidate, Roclatan. T…

Read the full story

Monday, May 15, 2017 | Clinical Trials, Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa

Aerie Pharmaceuticals reported that it has received notification from the FDA that the agency has completed its initial 60-day review of the Rhopressa new drug application (NDA) and determined that th…

Read the full story

Wednesday, April 12, 2017 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Reports Positive 6-Month Topline Safety and Efficacy Results for Rhopressa 0.02%

Aerie Pharmaceuticals reported the successful 6-month topline safety and efficacy results of its Rocket 4 phase 3 clinical trial for product candidate Rhopressa, a novel once-daily eye drop being test…

Read the full story

Monday, April 10, 2017 | Management/Leadership, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces Expansion of Commercialization Team

Aerie Pharmaceuticals announced the appointments of new employees Gary Menichini as Vice President of Sales, Dale Seibt as Vice President of Market Access, and Gerry McKenzie as Vice President of Comm…

Read the full story

Wednesday, March 08, 2017 | Earnings & Financials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Provides Update on Products in Development

As part of its fourth quarter and full-year earnings results reporting, Aerie Pharmaceuticals provided updates on several of its products in clinical development, including: Rhopressa (netarsud…

Read the full story

Wednesday, March 01, 2017 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces Resubmission of NDA for Rhopressa

Aerie Pharmaceuticals announced that it resubmitted its new drug application (NDA) for Rhopressa to the FDA after notification by its contract drug product manufacturer that the vendor’s Tampa, …

Read the full story
Load More